DLX4 and inflammatory breast carcinoma: 78.3% (18/23) of the HER2-negative IBC cases showed high DLX4 intensity, compared to 16.7% (1/6) in HER2 positive IBC cases (p < 0.05, Fisher's exact test) (Table 4).